WHO aims to have two billion coronar vaccines by 2021
Geneva: The World Health Organization said on Thursday that a few hundred million COVID-19 vaccine doses could be produced by the end of the year – and targeted those most vulnerable to the virus.
The United Nations health agency said it was working on that notion, with a vision of two billion doses by the end of 2021, as pharmaceutical companies rush to produce the vaccine.
WHO chief scientist Soumya Swaminathan said the researchers were working on more than 200 vaccine candidates from around the world, including 10 who are in human trials.
“If we are very lucky, there will be one or two successful candidates before the end of this year,” she told a virtual press conference.
She identified three groups in need of the first wave of vaccine supplements.
They are high-risk front-line workers, such as medics and police officers; Most victims of this disease, such as the elderly and diabetic patients; And people in high-transmission settings, such as urban slums and care homes.
Swaminathan said, “You have to start with the most vulnerable and then progressively vaccinate more people.”
“We are working on the assumption that we may have a hundred million dose later this year, very optimistically” she said.
“We’re hoping that in 2021 we’ll have two billion doses of one, two or three effective vaccines to be distributed worldwide. But there’s a big ‘if’, because we don’t yet have a vaccine that Be proven
“But because of all the investment that goes into it, we say we have two billion doses by the end of 2021 – we should at least be able to vaccinate these priority populations.”
Pharmaceutical company officials said at the end of last month that one or several COVID-19 vaccines could start rolling out before 2021, but warned that an estimated total of 15 billion doses would be needed to suppress the virus.
Swaminathan said scientists were analyzing 40,000 sequences of the new coronovirus and mutating all the viruses, making it far less than an influenza, and had not yet mutated in key regions that caused disease or immune responses. Will change the seriousness of.
The WHO on Wednesday decided to stop its trials of hydroxychloroquine as a treatment for hospitalized COVID-19 patients after evidence from its own work and others found it to reduce mortality. Did not take effect.
A decade-old malaria and rheumatic drug, hydroxychloroquine has been at the center of political and scientific controversy.
But Swaminathan said that ongoing non-WHO tests were trying to establish whether it could help prevent the disease before or after exposure to the virus.
It is being tested on health workers and others with increased risk for the virus in large, randomized trials.
“Hydroxychloroquine does not have – we know for sure – it has no effect” on the mortality rate of hospitalized COVID-19 patients, he said.
“Where there is still a difference: is there a role in its prevention or in reducing the severity in early infection?”
“For prophylaxis … the last word is not out yet,” she said.
Hydroxychloroquine was one of four drug or drug combinations in WHO’s Solidarity Trial: Randomized Clinical Trials – considered the gold standard for clinical screening – spread to hospital patients in many countries.
The purpose of the test is to rapidly discover whether certain drugs slow the progression of the disease or improve their chances of survival.